Atrial Cardiomyopathy
Key result
Atrial cardiomyopathy is linked to increased stroke risk and arrhythmia progression in AF.
Why the study?
Following a recent multi-society consensus document on atrial cardiomyopathy, the authors aimed to critically consider the added clinical value and meaningfulness of this concept.
Design
Review
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is an area of intensive research. Several investigators have reported metabolic changes in atrial tissue. Others have highlighted the importance of interstitial fibrosis. But because the atrial wall is so thin, it is difficult to assess these changes in vivo and in patients reliably. For this reason, the research community has focused on risk factors and on plasma, imaging or EKG-derived biomarkers of atrial cardiomyopathy and cardioembolic stroke risk. Much research is ongoing, but to date it remains unclear whether this effort will translate into practical solutions that will improve risk assessment and prevention of cardioembolic stroke.”
AGAndreas GoetteCardiologist, St. Vincenz Hospital Paderborn
“Our aim is to further improve the prevention and treatment of atrial fibrillation. Atrial fibrillation has many different causes. It is therefore important to describe the underlying pathology and develop tailored therapies for atrial fibrillation based on the actual causes. The classification enables individualized therapy that offers patients the best possible treatment success.”
AGAndreas GoetteCardiologist, St. Vincenz Hospital Paderborn
“Atrial cardiomyopathies contribute to the development of atrial fibrillation, which is the most common heart rhythm disturbance. They can also lead to atrial clots and consequent stroke, and therefore have substantial clinical significance.”
Implication
Atrial cardiomyopathy is an emerging concept that may independently contribute to stroke risk in atrial fibrillation and guide future management strategies, though clinical trials are needed to validate its utility.
Key Points
- To evaluate the clinical validity and utility of the atrial cardiomyopathy concept in understanding stroke risk, arrhythmia progression, and management strategies in atrial fibrillation.
- Synthesized consensus framework from international electrophysiology societies (EHRA, HRS, APHRS, SOLAECE) across definition, histopathology, physiology, mapping, and ablation.
- Critically reviewed clinical and pathophysiological evidence linking atrial cardiomyopathic properties to thromboembolism and rhythm control.
- Identified atrial cardiomyopathy as an independent contributor to thromboembolic stroke risk beyond the presence of atrial fibrillation alone.
- Demonstrated that characterizing atrial cardiomyopathic changes provides a mechanistic basis for refining stroke prevention, rhythm maintenance, and rate control strategies.
PICO
P
Population
Atrial cardiomyopathy and atrial fibrillation
E
Exposure / Comparator
Atrial cardiomyopathy
Atrial cardiomyopathy is an emerging concept that may independently contribute to stroke risk in atrial fibrillation and guide future management strategies, though clinical trials are needed to validate its utility.
Cite This Study
Guichard et al. (2017) conducted a review in Atrial cardiomyopathy and atrial fibrillation. Atrial cardiomyopathy was evaluated. Atrial cardiomyopathy is implicated as an independent contributor to stroke risk in atrial fibrillation and a determinant of arrhythmia progression, though clinical trials are needed to define its value.